• Drug Safety Monitoring Board Member

    Professor Peter Gibson

    Professor Peter Gibson is the Director of Gastroenterology at The Alfred and Monash University, having previously been Professor of Medicine at Eastern Health and Head of the Eastern Health Clinical School. He is a Past-President of the Gastroenterological Society of Australia. From a background of research in epithelial cell biology, he now directs a large program of translational research, and has active clinical interests in inflammatory bowel disease, coeliac disease and irritable bowel syndrome. A major focus of his work is the use of diet to control gut symptoms and influence outcomes in chronic intestinal conditions such as irritable bowel syndrome and inflammatory bowel disease. He has published widely on these topics. He was awarded the Distinguished Research Prize by the Gastroenterological Society of Australia in 2010.
  • Advisory Board Member

    Doctor Rebecca Burgell

    Dr Rebecca Burgell is a consultant gastroenterologist with an interest in inflammatory bowel disease, clinical nutrition, pelvic floor dysfunction and functional gastrointestinal disorders. She is the Head of the Functional Gastrointestinal disorders service and medical lead of the home enteral nutrition program at Alfred Health. Dr Burgell has a PhD from the University of London examining the physiology of the lower bowel in patients with severe functional constipation at the National centre for bowel research and surgical innovation based at Bart’s Health in London. She is expert in performing anorectal physiology investigations and endoanal ultrasound and is a member of the International Anorectal Physiology Working Group. Dr Burgell currently works fulltime at Alfred Health and Monash University.
  • Drug Safety Monitoring Board member

    Doctor Jakob Begun

    Dr Jakob Begun obtained his MD and PhD in genetics at Harvard Medical School. His advanced training in Gastroenterology and Inflammatory Bowel Disease (IBD) was at Massachusetts General Hospital (MGH) where he developed a keen interest in the microbiome – immune system interactions. He returned to Australia in 2014 to pursue his interest in clinical IBD and research. He is the IBD clinical lead at the Mater Hospital Brisbane and IBD Group leader at the Mater Research Institute – University of Queensland. He runs a basic and translational laboratory investigating the interaction between innate immune functions of the gut and the microbial community. He also performs clinical research examining the natural history of IBD, endoscopic assessment and intervention, and identifying barriers of care for adolescents and young adults with IBD at the Mater Young Adult Health Centre. He serves on the steering committees of the Australia and New Zealand IBD Consortium and the Australian IBD Association.
  • Advisory Board Member

    Laureate Professor Nick Talley

    Laureate Professor Nick Talley is currently Pro Vice-Chancellor, Global Research at the University of Newcastle, Australia. He is a clinician, educator and researcher, with extensive experience as a leader in the medical and University sectors. He previously held an appointment as Pro Vice-Chancellor (and Dean) of the Faculty of Health and Medicine at the University of Newcastle from 2010-2015, and was seconded to be the Deputy Vice-Chancellor-Research (Acting) at the University of Newcastle from June 2013 to March 2014.

    Professor Talley is a neurogastroenterologist, has published over 1000 papers in the peer-reviewed literature, and is a leading medical educator and the author of the highly regarded textbooks Clinical Examination and Examination Medicine. Professor Talley is also a Senior Staff Specialist and gastroenterologist at John Hunter Hospital. He currently holds adjunct research appointments as Professor at Mayo Clinic, University of North Carolina and the Karolinska Institute, Stockholm, Sweden .
  • Advisory Board Member

    Professor Jane Andrews

    Jane Andrews is Head of the IBD Service & Education at the Department of Gastroenterology & Hepatology of The Royal Adelaide Hospital in Australia and a Clinical Professor at the School of Medicine, University of Adelaide. Professor Andrews has a long clinical research interest and many years practical experience in managing both IBD and other luminal, especially functional, gastrointestinal disorders. She has an interest in clinical audit, value in care, clinical outcomes research and healthcare system delivery.

    Professor Andrews is an active researcher in many aspects of clinical Gastroenterology. Particular interests include examining health access, models of care and equity issues in addition to optimising and auditing standard clinical management and trying to improve systems design. Whilst much of her research is focussed on IBD, she also has expertise in Functional GI disease and is also published in hepatology care especially with regard to psychological comorbidities and healthcare utilisation. Her current research collaborators include psychologists, mucosal immunologists, microbiologists, and specialist IBD nurses. Current studies have included Faecal Microbiota Transplantation in ulcerative colitis, examining routine psychological care in IBD, new models of care for FGID and dietary issues in IBD. She also collaborated nationally and internationally via active membership of the ANZ IBD Consortium www.ANZIBDC.org . She sits on their management committee and is also a board member of the IBD-Specific charity, Crohn’s Colitis Cure. c-c-cure.org . Via the ANZIBDC she participates in the international IBD Genetics Consortium work. Professor Andrews is also a Board Member of GESA www.GESA.org.au

    Professor Andrews has authored over 120 publications, 3 book chapters and supervised 7 completed PhD students. She has substantial experience with undergraduate & postgraduate medical education, mentorship & clinical leadership.
  • Advisory Board Member

    Professor Barry Campbell

    Professor Barry Campbell holds a professorship in University of Liverpool’s Institute of Translational Medicine. Barry started his scientific career in gut endocrine physiology at UCNW Bangor, receiving a BSc with Honours in Zoology in 1988, and a PhD in Physiology from University of Liverpool in 1991. Following an MRC-funded post-doctoral research position, he held a Wellcome Trust-funded lectureship in intestinal physiology, before being appointed to a full-time academic post in Medicine at Liverpool where his research led to specific understanding of the causes and consequences of altered intestinal mucosal glycosylation that occurs in intestinal inflammation and cancer.

    Professor Campbell now leads one of the key international translational research groups investigating bacteria-host intestinal epithelium interactions, particularly focused on Crohn’s disease- and colorectal cancer-mucosa associated Escherichia coli. This includes laboratory studies on epithelial and immune cell responses in 2D cell-line and 3D organoid cultures, and in ex vivo tissue, and translational medicine projects examining effects of antibiotics, environment modulating agents and dietary components. He was awarded a Personal Chair within the University of Liverpool’s Institute of Translational Medicine in 2013. He is a member of the UK Gut Microbiota for Health Expert Panel and the ‘Scientists in Gastroenterology’ lead for the British Society of Gastroenterology, supporting education, research and the annual meeting Translational Science Masterclass symposia.
  • Advisory Board Member

    Associate Professor Simon Keely

    Dr Keely is chief investigator of the Hunter Medical Research Institute (HMRI) Gastrointestinal Research Group. Dr Keely graduated with a Ph.D. from University College Dublin. He undertook postdoctoral research training at the Mucosal Inflammation Program in University of Colorado Denver, receiving a prestigious fellowship from the Crohn's and Colitis Foundation of America. His research group at the HMRI is a multidisciplinary team of biomedical and clinician researchers investigating the molecular mechanisms of gastrointestinal diseases such as inflammatory bowel disease, colorectal cancer and functional GI disorders. Dr Keely is particularly interested in understanding changes in both tissue metabolism and host-microbe interactions during mucosal inflammation and how these changes relate to GI immunopathology and loss of immune homeostasis. The ultimate goal of this research is to understand how these factors can be manipulated for therapeutic benefit. Dr Keely has specialist expertise in in vitro, ex vivo and in vivo models of IBD and IBS. His work been published in leading gastroenterology and basic laboratory science journals and he is a consultant for a number of pharmaceutical companies.
  • Advisory Board Member

    Doctor Tracey Brown

    Dr Brown obtained her PhD in Biochemistry from Monash University, and has worked in academic and commercial research institutions in the USA, Europe and Australia where she focused on developing products for the treatment of cancer, inflammation and anti-aging.

    Over the last 20 years, Tracey has built, managed and lead international product development teams which have taken products from conception through to registration. Through this process, Tracey has developed extensive experience in the identification and evaluation of suitable commercialisation assets, manufacture of chemical and biological therapeutics, development and implementation of preclinical and clinical development plans, clinical program management, regulatory affairs, interaction with international regulatory agencies and product reimbursement processes.

    Dr Brown joined Anatara in September 2016 as Chief Development Officer where she was responsible for the direction and management of the human product development program. Dr Brown looks forward to continuing to support and guide Anatara's program as a member of the product development advisory board.

    Prior to joining Anatara, Tracey was a co-founder of the ASX-listed company, Meditech; the Chief Scientific Officer of Alchemia and has acted as a director on the board of both listed and private biotechnology companies. Tracey also holds an adjunct Associate Professorship at Monash University where she participates in the commercialisation of research and the mentoring of academic researchers to assist in their transition into the biotechnology industry.
  • Drug Safety Monitoring Board member

    Professor Paul Rolan

    Paul is a clinical pharmacologist, drug developer and pain management physician. After obtaining specialist qualifications in general medicine and clinical pharmacology he spent two years as Director of Medicine at Cairns Base Hospital. Subsequently Paul joined the pharmaceutical industry in the UK, initially working for Wellcome Research Laboratories where he was Head of Clinical Pharmacokinetics. In 1994 he became Medical Director of Medeval, a clinical pharmacology contract research organisation spun out of the University of Manchester. Under Paul's leadership, Medeval became the largest clinical pharmacology contract research organisation in the United Kingdom. He was part of a management buy out team of the Company from the University and a subsequent trade sale three years later to ICON Clinical Research. he has been Principal Investigator in over 700 clinical research studies and has been an active Consultant, both to the pharmaceutical industry as well as an invited speaker to the FDA.